ChengDa PharmaCeuticals Co., Ltd. Class A

ChengDa PharmaCeuticals Co., Ltd. Class A

SSZSE:301201
21.16
CNY
-0.54
(-2.49%)
-0.27EPS
4.72BMarket Cap
2008 Y
2009 Y
2010 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
39.38
1.64
2.15
1.9
1.88
2.77
3.21
3.58
2.72
2.68
2.19
2.68
3.15
Basic EPS, GAAP
8
0.26
0.39
0.04
0.06
0.51
1.04
0.87
0.7
0.59
-0.18
-0.08
-0.27
Free Cash Flow per Basic Share
- -
-0.33
0.07
- -
0.21
0.15
0.56
-0.48
-1.04
-0.21
-1.7
-0.23
- -
Dividend per Share
4.47
0.26
0.33
0.07
0.07
0.27
0.2
0.27
0.29
0.19
0.2
0.22
0.22
Book Value per Share
0.35
0.77
1.06
2.52
2.58
3.07
3.95
4.56
14.31
14.72
13.85
13.54
13.26
Tangible Book Value per Share
0.33
0.56
0.86
2.32
2.4
2.92
3.59
4.22
14.09
14.5
13.62
13.3
13.03
Basic Weighted Avg Shares
3
80
80
106
108
106
116
116
151
155
152
152
151
Sales/Revenue/Turnover
132
131
172
202
203
294
373
416
411
414
333
406
477
Operating Margin (%)
21.72
18.45
21.08
8.32
6.3
24.4
27.86
29.53
21.81
14.63
-17.45
3.32
-0.89
Depreciation Expense
- -
4
6
23
27
27
26
30
35
41
47
73
- -
Net Income, GAAP
27
21
31
4
7
54
121
100
106
91
-28
-12
-41
Effective Tax Rate (%)
- -
12.87
10.74
10.64
6.14
13.22
14.27
13.02
11.35
12.61
- -
- -
- -
Profit Margin (%)
20.31
15.99
18.29
2.03
3.3
18.45
32.48
24.16
25.88
21.96
-8.44
-2.93
-8.62
Working Capital
6
16
34
-37
-32
41
104
78
1,580
1,471
1,208
1,101
1,024
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
80
44
37
Total Equity
37
83
115
273
280
357
459
530
2,216
2,279
2,146
2,097
2,054
Return on Invested Capital (%)
- -
31.01
24.8
2.25
2.06
12.75
26.07
19.16
7.82
4.19
- -
- -
- -
Return on Capital (%)
- -
32.03
26.16
3.71
10.34
20.59
27.86
19.07
7.58
4.04
- -
- -
- -
Return on Common Equity (%)
- -
34.68
31.84
2.11
2.43
17.06
29.76
20.35
7.76
4.05
-1.27
-0.56
-1.95

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
15
15
15
LT Borrowings
44
37
37
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
155
155
155
Market Capitalization
7,999
5,625
4,717

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,301
1,320
1,249
Cash, Cash Equivalents & STI
964
985
930
Accounts Receivable, Net
133
118
110
Inventories
147
166
166
Total Current Liabilities
172
202
225
Payables & Accruals
- -
- -
- -
ST Debt
15
15
15
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
56.29%
65.68%
-2.27%
Free Cash Flow
-581.89%
104.79%
-86.42%
Net Income, GAAP
64.5%
-42.82%
-57.56%
Sales/Revenue/Turnover
13.46%
2.7%
21.99%
Total Cash Common Dividend
27.57%
11.18%
7.44%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
101
63
80
89
333
2025
76
106
- -
121
406
2026
128
127
100
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.04
0.1
-0.45
-0.18
2025
-0.01
0.09
- -
-0.19
-0.08
2026
0.05
-0.03
-0.1
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.19
0.01
0.2
2025
- -
- -
- -
0.01
0.22
2026
- -
- -
0.2
- -
- -

Company Description

CEO
Gang Lu
Full Time Employees
659
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Jiaxing China
IPO Date
Jan 20, 2022
Business
ChengDa PharmaCeuticals Co., Ltd. is a China-based contract research, development, and manufacturing organization (CRDMO) and fine chemical manufacturer specializing in active pharmaceutical ingredients (APIs), advanced pharmaceutical intermediates, and specialty nutritional additives. The company operates through two core business segments: Custom Development and Manufacturing (CDMO/CRDMO) Services and L-Carnitine Series Products. Its primary products and service offerings include customized process development, route scouting, analytical validation, and cGMP commercial manufacturing of small-molecule APIs and key registered intermediates for clinical and commercial-stage therapeutics targeting oncology, antiviral, central nervous system, cardiovascular, and metabolic disorders; pharmaceutical-grade levocarnitine (L-carnitine base), L-carnitine L-tartrate, acetyl-L-carnitine hydrochloride, L-carnitine hydrochloride, and L-carnitine fumarate used in medical formulations for cardiomyopathy and chronic renal disease; food, dietary supplement, infant nutrition, and animal feed additives; generic APIs and regulatory starting materials including brivaracetam and dapagliflozin intermediates; and specialized building blocks for emerging modalities, including phosphoramidite monomers and GalNAc delivery platform conjugates for oligonucleotide (siRNA/ASO) therapeutics, as well as intermediates for small-molecule GLP-1 receptor agonists. Founded in 1999 and headquartered in Jiashan County, Jiaxing, Zhejiang Province, China, the company distributes its products domestically and exports to more than 30 countries and regions across North America, Europe, and the Asia-Pacific region, operating manufacturing facilities compliant with international standards, including U.S. FDA, Japanese PMDA, and ISO/FSSC certifications. Recent corporate developments include the successful completion of an on-site U.S. FDA cGMP inspection with No Action Indicated (NAI) status at its Jiaxing manufacturing site in late 2024; a strategic minority equity investment of RMB 70 million in Chengdu Speikang Biomedical Technology Co., Ltd. in 2025 to strengthen contract research (CR) integration and API co-development; the expansion into regenerative medicine via its biopharmaceutical subsidiary Shanghai Jiuqiancheng Biomedical through a strategic technology licensing alliance with Chiron Pharma for stem cell therapies; and the completion, environmental validation, and commissioning of upgraded manufacturing lines and expanded research facilities for high-potency APIs, specialized intermediates, and L-carnitine derivatives.